Home › Small Cell Lung Cancer › Washington › Seattle
Small Cell Lung Cancer clinical trials in Seattle, WA
12 studies for Small Cell Lung Cancer are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RecruitingPhase 1/2
- Virginia Mason Medical Center, Seattle
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
RecruitingPhase 3
- Swedish Medical Center, Seattle
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
RecruitingPhase 1/2
- Fred Hutchinson Cancer Center, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Seattle
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
RecruitingPhase 1
- Fred Hutch Cancer Center, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
RecruitingPhase 1
- Fred Hutchinson Cancer Research Center, Seattle
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- University of Washington Fred Hutchinson, Seattle
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
RecruitingPhase 1/2
- Fred Hutch Cancer Research, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RecruitingPhase 1/2
- Fred Hutch Cancer Center, Seattle
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RecruitingPhase 1/2
- Swedish Cancer Institute, Seattle
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
RecruitingPhase 1
- Swedish Cancer Institute, Seattle
Small Cell Lung Cancer trials in other cities
- Houston, TX26 studies
- New York City, NY23 studies
- Arlington, VA22 studies
- Boston, MA22 studies
- Los Angeles, CA20 studies
- Nashville, TN20 studies
- Orlando, FL14 studies
- Chicago, IL13 studies
- Cleveland, OH13 studies
- Dallas, TX13 studies
- St. Louis, MO13 studies
- Washington, DC13 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer55 studies
- Cancer (all types)48 studies
- Prostate Cancer45 studies
- Acute Myeloid Leukemia40 studies
- Metastatic Cancer39 studies
- Breast Cancer37 studies
- Colorectal Cancer35 studies
- Lung Cancer34 studies
- Ovarian Cancer29 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia22 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.